期刊文献+

核基质蛋白22在非肌层浸润性膀胱癌患者预后监测中的作用 被引量:3

The function of nuclear matrix protein 22 in the prognosis of patients with non muscle-invasive bladder cancer
下载PDF
导出
摘要 目的探讨核基质蛋白22(nuclear matrix protein 22,NMP22)在非肌层浸润性膀胱尿路上皮细胞癌患者术后复发监测中的作用。方法选取62例非肌层浸润性膀胱尿路上皮细胞癌患者,以51例成人健康体检者为对照,比较两组患者之间尿NMP22的水平有无差异;并以NMP22值>10.0U/ml为临界点,将膀胱尿路上皮细胞癌患者分为NMP22升高组和NMP22正常组,用log-rank检验这两组患者的复发时间的差异。结果膀胱尿路上皮细胞癌患者的尿NMP22水平(平均秩和=81.18)高于对照组(平均秩和=27.61)(U=82,P<0.001);NMP22升高组患者的复发时间[(28.71±1.18)]月早于NMP22正常组的[(33.20±1.82)]月(χ2=4.313,P=0.038)。结论尿NMP22检查较适合于在基层医院进行膀胱尿路上皮细胞癌患者术后的随访。 Objective To study the monitoring function of nuclear matrix protein22(NMP22) for operation relapse in patients of non muscle-invasive bladder cancer.Methods 62 non muscle-invasive bladder cancer patients and 51 adults with health examination for controls were collected to compare NMP22 concentration in urine.Patients were divided into high level NMP22 group and the normal NMP22 group for with the critical point for NMP2210.0U/ml,log-rank test was used to compare the difference between the two group.Results ①The urine NMP22 concentration in patients of non muscle-invasive bladder cancer(mean rank =81.18)were higher than those of control's(mean rank=27.61)(U=82,P0.001).②The relapse time of the high level NMP22 group(28.71±1.18)months were shorter than the normal group(33.20±1.82)months(χ2=4.313,P=0.038).Conclusions Urine NMP22 was an optincal factor for follow up visit for patients with non muscle-invasive bladder cancer in rural district hospital.
出处 《现代泌尿生殖肿瘤杂志》 2011年第4期223-225,共3页 Journal of Contemporary Urologic and Reproductive Oncology
关键词 膀胱肿瘤 核基质相关蛋白类 复发 Urinary bladder neoplasms Nuclear matrix associated proteins Recurrence
  • 相关文献

参考文献13

二级参考文献15

  • 1魏矿荣,陈振雄,梁智恒,何方方,林茂合,欧小文.中山市1970~1999年膀胱癌发病趋势分析[J].中国肿瘤,2005,14(4):235-237. 被引量:28
  • 2David SS,Gennaro AC ,Julio RV,et al. Evaluation of NMP 22 in the detection of transitional cell carcinoma of the bladder. J Urol, 1998,159:394-398.
  • 3Sarosdy MF, de Vere WW, Soloway MS, et a.l. Results of a multicenter trial using BTA test to monitor for and diagnosis recurrent bladder cancer. J Urol, 1995,154:379-384.
  • 4Landman J, Chang YL, Kavaler E, et al. Sensitivity and specificity of NMP 22, telomerase and BTA in the detection of human bladder cancer. Urology, 1998,52:398-402.
  • 5Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear matrix proteins for cancer diagnosis. CRC Crit Rev Eukaryotic Gene Exp,1996, 6: 189-214.
  • 6Kang HL. Evaluation of the NMP 22 test and comparison with voide durine cytology in the detection of bladder cancer. Yonsei Med J,2001, 42:14-18.
  • 7Sozen S, Biri H, Sinik Z, et al. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol, 1999,36 : 225-229.
  • 8Sharma S, Zippe CD, Pandrangi L, et al. Exclusion criteria enhance the specificity and positive predictive value of NMP 22 and BTA stat.J Urel, 1999,162:53-57.
  • 9Landman J,Urology,1998年,52卷,398页
  • 10Parkin DM,Bray F,Ferlay J,et al. Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.

共引文献23

同被引文献32

  • 1张绍谨,刘红耀.尿膀胱癌抗原、核基质蛋白22和透明质酸诊断膀胱癌的临床价值[J].中华临床医师杂志(电子版),2011,5(24):7202-7205. 被引量:15
  • 2何朝宏,肖传国,杜茂信.尿核基质蛋白22在膀胱癌术后复发监测中的应用[J].临床泌尿外科杂志,2005,20(2):107-108. 被引量:3
  • 3曾辉,林僖,陈孝岳,刘隆忠,赵雁梨.经直肠或经阴道腔内超声在膀胱癌术前分期中的应用价值[J].中华泌尿外科杂志,2005,26(2):135-135. 被引量:14
  • 4Ecke TH. Focus on urinary bladder cancer markers: a review[J]. Minerva Urol Nefrol, 2008, 60(4) : 237-246.
  • 5Jemal A, Siegel R, Xu J, et al. Cancer statistics,2010[J]. CA Cancer J Clin, 2010, 60(5) : 277-300.
  • 6Soloway MS, Briggman V, Carpinito GA, et al. Use of a new mark- er, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment[J]. J Urol, 1996, 156(21 Pt) : 363-367.
  • 7Ann JS, Kim HS, Chang SG, et al. The clinical usefulness of nu- clear matrix protein-22 in patients with atypical arine cytology [ J]. Korean J Urol, 2011, 52(9) : 603-605.
  • 8Arora VK, Sarungbam J, Bhatia A, et al. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carci- noma[J]. Diagn Cytopathol, 2010, 38(11) : 788-790.
  • 9Keesee SK, Briggman JV, Thill G, et al. Utilization of nuclear ma- trix proteins for cancer diagnosis [ J ]. Crit RevEukayotic Gene Expr, 1996, 6(2/3): 189-214.
  • 10Sharmat S, Zippe CD, Pandrangi I, et al. Exclusion criteria en- hance the specificity and positive predictive value of NMP22 and BTAstat[J]. JUrol, 1999, 162(1): 53-57.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部